Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 13,518 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Blood Clear all
Completed Not applicable Interventional Results available

High-Flow Nasal Cannula and Desaturation Episodes in the Morbidly Obese Patients

NCT03148262
View directory record Official record
Conditions
Desaturation of Blood, Obesity, Colonoscopy, Sleep Apnea, High Flow Nasal Cannula
Interventions
The Comfort Flo system, The Salter nasal cannula
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 28, 2026, 4:28 PM EDT
Completed Not applicable Interventional

Integrated Treatment of Marijuana Abuse for HIV+ Youth

NCT00683488
View directory record Official record
Conditions
HIV Infections
Interventions
Focus Group, First Intervention Trial, Intervention Trial 2
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 28, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Results available

Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study

NCT02300103
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
San Diego, California • San Marcos, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 28, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Results available

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

NCT00515827
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir (MK-0518), Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 28, 2026, 4:28 PM EDT
Recruiting Phase 1Phase 2 Interventional

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

NCT03190941
View directory record Official record
Conditions
Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer, Colon Cancer, Rectal Cancer
Interventions
Cyclophosphamide, Fludarabine, Anti-KRAS G12V mTCR PBL, Aldesleukin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 28, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

NCT02185794
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 28, 2026, 4:28 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma

NCT01101594
View directory record Official record
Conditions
Multiple Myeloma
Interventions
hLL1-DOX (the doxorubicin conjugate of milatuzumab)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Orlando, Florida • Atlanta, Georgia • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 28, 2026, 4:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Abbott Laboratories Alinity s Blood Screening Assays - Clinical Evaluation Protocol

NCT03285295
View directory record Official record
Conditions
Healthy
Interventions
Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay, Alinity s HTLV I/II Assay, Alinity s Anti-HCV Assay, Alinity s HIV Ag/Ab Combo Assay, Alinity s Anti-HBc Assay, Alinity s Chagas Assay
Device
Lead sponsor
Abbott Diagnostics Division
Industry
Eligibility
16 Years and older
Enrollment
106,881 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
5
States / cities
Boca Raton, Florida • St Louis, Missouri • Knoxville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 28, 2026, 4:28 PM EDT
Not listed Phase 1 Interventional

Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.

NCT01165762
View directory record Official record
Conditions
ESRD
Interventions
Immune Tolerance
Drug
Lead sponsor
Everett Meyer
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
2
States / cities
Stanford, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 28, 2026, 4:28 PM EDT
Completed Phase 1 Interventional

Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

NCT00446342
View directory record Official record
Conditions
B-lymphoid Malignancies, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma
Interventions
SNS-032 Injection
Drug
Lead sponsor
Sunesis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 28, 2026, 4:28 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

An mHealth Intervention to Improve HIV Prevention Service Engagement Among People Who Use Drugs

NCT06068283
View directory record Official record
Conditions
HIV Infections
Interventions
LOTUS mHealth Intervention Group
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 28, 2026, 4:28 PM EDT
Completed Phase 3 Interventional

Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter

NCT00006083
View directory record Official record
Conditions
Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific, Veno-occlusive Disease
Interventions
Fragmin, placebo
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 28, 2026, 4:28 PM EDT
Not listed No phase listed Observational

Correlation Between PIF Maternal Serum Levels and Pregnancy Outcome

NCT01805102
View directory record Official record
Conditions
Pregnancy
Interventions
Not listed
Lead sponsor
BioIncept LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Oct 28, 2026, 4:28 PM EDT
Completed Not applicable Interventional

Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction

NCT00816127
View directory record Official record
Conditions
Liver Cirrhosis, Coagulopathy
Interventions
Desmopressin, blood transfusion
Drug · Biological
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2009 · Synced Oct 28, 2026, 4:28 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

NCT06385483
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Afatinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 28, 2026, 4:28 PM EDT
Completed Not applicable Interventional

Clinical Effectiveness of Boxing Training in Individuals With Elevated Blood Pressure or Stage 1 Hypertension

NCT06413251
View directory record Official record
Conditions
Elevated Blood Pressure, Hypertension
Interventions
Boxing Training, Control flexibility
Other
Lead sponsor
University of Texas, El Paso
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 28, 2026, 4:28 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion

NCT03347422
View directory record Official record
Conditions
Cold Agglutinin Disease
Interventions
sutimlimab (BIVV009), placebo
Drug
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Tucson, Arizona • Los Angeles, California • Georgetown, District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 28, 2026, 4:28 PM EDT
Completed Phase 2 Interventional

Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma

NCT00004902
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
tocladesine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Oct 28, 2026, 4:28 PM EDT
Completed Phase 1 Interventional

Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS

NCT00000646
View directory record Official record
Conditions
HIV Infections
Interventions
Pentoxifylline
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 28, 2026, 4:28 PM EDT
Completed Not applicable Interventional

An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.

NCT00002173
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Immunogen
Biological
Lead sponsor
The Immune Response Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 4:28 PM EDT
Not listed Not applicable Interventional

Tranexamic Acid in Orthopaedic Trauma Surgery

NCT02080494
View directory record Official record
Conditions
Blood Loss, Trauma, Fracture, Surgery
Interventions
Tranexamic Acid
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 28, 2026, 4:28 PM EDT
Recruiting Phase 2 Interventional

HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

NCT03850366
View directory record Official record
Conditions
Hematological Malignancy
Interventions
Bortezomib
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 28, 2026, 4:28 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Blood Flow Restriction Training for People With Disabilities

NCT06441422
View directory record Official record
Conditions
Weakness, Muscle
Interventions
Blood flow restriction training, No blood flow restriction training
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 28, 2026, 4:28 PM EDT
Completed Phase 2 Interventional

ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections

NCT00035945
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
ISIS 14803
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 28, 2026, 4:28 PM EDT